NASDAQ:IPA - Nasdaq - CA45257F2008 - Common Stock - Currency: USD
IMMUNOPRECISE ANTIBODIES LTD
NASDAQ:IPA (2/4/2025, 8:00:02 PM)
After market: 0.4502 -0.02 (-3.39%)0.466
+0.03 (+5.67%)
The current stock price of IPA is 0.466 USD. In the past month the price decreased by -10.37%. In the past year, price decreased by -78.43%.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Curious about the most active stocks on Wednesday? Find out which stocks are dominating the market action!
Top movers in Wednesday's session
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.56 | 222.07B | ||
DHR | DANAHER CORP | 28.71 | 155.30B | ||
A | AGILENT TECHNOLOGIES INC | 27.8 | 41.93B | ||
IQV | IQVIA HOLDINGS INC | 18.42 | 36.31B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 35.12 | 28.27B | ||
WAT | WATERS CORP | 36.03 | 24.37B | ||
WST | WEST PHARMACEUTICAL SERVICES | 48.97 | 23.97B | ||
ILMN | ILLUMINA INC | 71.79 | 19.70B | ||
ICLR | ICON PLC | 13.78 | 15.96B | ||
RVTY | REVVITY INC | 25.13 | 14.99B | ||
AVTR | AVANTOR INC | 22.46 | 14.98B | ||
TECH | BIO-TECHNE CORP | 40.53 | 11.53B |
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Victoria, British Columbia. The firm owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. The company has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The firm utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
IMMUNOPRECISE ANTIBODIES LTD
3204-4464 Markham St.
Victoria BRITISH COLUMBIA CA
Employees: 87
Company Website: https://www.ipatherapeutics.com/
Investor Relations: https://www.immunoprecise.com/investors/
Phone: 16048060626
The current stock price of IPA is 0.466 USD.
The exchange symbol of IMMUNOPRECISE ANTIBODIES LTD is IPA and it is listed on the Nasdaq exchange.
IPA stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IPA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IPA.
IPA does not pay a dividend.
IPA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
The outstanding short interest for IPA is 0.14% of its float.
ChartMill assigns a technical rating of 2 / 10 to IPA. When comparing the yearly performance of all stocks, IPA is a bad performer in the overall market: 92.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IPA. IPA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months IPA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS decreased by 28.13% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.92% | ||
ROE | -84.27% | ||
Debt/Equity | 0.45 |
ChartMill assigns a Buy % Consensus number of 80% to IPA. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 14.37% and a revenue growth 0.58% for IPA